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Background: The brain is a common site of recurrence in melanoma patients. Brain recurrence may present as a seizure, hemorrhage, or death. We
sought to determine predictors of brain metastases in patients with primary and regional melanoma in order to facilitate targeted screening.
Methods: Prospectively maintained databases were used to identify patients treated for local or regional melanoma who developed stage IV
melanoma with and without brain metastasis at initial recurrence. One hundred twenty patients were identiﬁed with brain relapse and compared to
487 patients without brain recurrence.
Results:On univariate analysis, patients with brain metastases were younger (55 vs. 59yrs, P¼ 0.04) but did not differ in primary site (head and neck
23% vs. 21%, P¼ 0.20). Brain metastasis patients had thinner primaries (mean 3.4 vs. 4.5mm, P¼ 0.01). There were no other pathologic differences
including ulceration (55% vs. 53%,P¼ 0.75), mitoses (7 vs.7.5,P¼ 0.61) or histologic subtype. Younger age and decreased Breslow thickness were
independently associated with brain metastases at stage IV recurrence (OR¼ 1.10 P¼ 0.01 and OR¼ 1.02 P¼ 0.02, respectively).
Conclusions:Our analysis, the largest to date, demonstrates that thinner Breslow depth and younger age were associated with brain recurrence at ﬁrst
presentation with Stage IV disease.
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INTRODUCTION
The role of cross‐sectional imaging following treatment of clinically
localized melanoma, as deﬁned by the National Comprehensive Cancer
Network (NCCN) is limited, with routine history and physical exam
considered adequate in the absence of symptoms of recurrent
disease [1]. Patients with stage III disease are more commonly
subjected to routine imaging, particularly during the ﬁrst 3 years
following treatment. While signs and symptoms of visceral recurrence
may be subtle, such as vague discomfort, fatigue, or nausea, recurrence
in the brain may result in seizure, mental status changes or paralysis [2].
Current surveillance guidelines do not recommend routine brain
imaging for asymptomatic patients with stage I–III melanoma [1,3]. If a
high‐risk population could be identiﬁed, however, targeted screening
could be offered, potentially allowing for diagnosis and treatment prior
to development of symptoms.
While no data exists regarding the impact of early detection of brain
lesions on survival, prompt treatment with radiotherapy or surgical
resection may decrease the likelihood of neurologic catastrophe due to
edema, hemorrhage, or herniation [4,5]. We identiﬁed patients treated
for primary and/or regional melanoma who developed brain metastases
as part of their ﬁrst distant recurrence. Baseline demographic
characteristics and histopathologic data were used to compare these
patients to those who developed distant non‐CNS metastases in order to
identify predictors of brain metastasis as a component of systemic
relapse.
PATIENTS AND METHODS
Approval for this study was obtained by the Institutional Review
Boards (IRB) of Memorial Sloan‐Kettering Cancer Center (MSKCC)
and the University of Michigan Medical Center (UMMC).
Study Patients
Prospectively maintained melanoma databases were queried to
identify patients who underwent resection of primary or regional
cutaneous melanoma at UMMC or MSKCC, and subsequently
developed distant metastatic disease during follow‐up. Patients under
the age of 18, no evidence of distant metastatic disease, or lost to follow‐
up were excluded from analysis. Those who presented with Stage IV
disease at the time of their initial diagnosis and those with uveal or
mucosal melanoma were also excluded.
Patient and Tumor Characteristics
Patient characteristics were collected from hospital records and
included: gender, age, location of the primary melanoma (head/neck,
trunk, lower extremity, and upper extremity) and stage at diagnosis.
Histologic features of the primary melanoma were reported by
pathologists with extensive experience in dermatopathology and
included: Breslow thickness (in millimeters), Clark level, mitotic rate
per square millimeter, histologic subtype, ulceration, perineural and
lymphovascular invasion, regression, immune inﬁltrate and satellitosis.
Sentinel lymph node (SLN) biopsy was performed, when appropriate, as
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previously described [6]. Although there was no absolute standard
protocol for post‐treatment follow‐up, most patients with stage I and II
melanoma were examined every 3–6 months. Yearly chest X‐rays, LDH
levels, liver function tests, and CBCs were obtained when deemed
appropriate, but were not routine. Only new symptoms or locoregional
recurrence prompted evaluation with cross‐sectional imaging using CT
scanning, PET/CT scanning, or MRI. Patients who were without
evidence of disease following treatment for stage III melanoma were
more likely to undergo routine cross‐sectional imaging with PET/CT or
CT scanning compared to those with stage I or II disease, particularly for
the ﬁrst 2 to 3 years following surgery. Routine CNS imaging was not
employed, however, brain imaging (usually MRI) was routinely
performed in patients diagnosed with stage IV disease.
Statistical Analysis
Nominal variables were evaluated using two‐tailed x2 or Fisher’s
exact tests when appropriate. Continuous variables were assessed with
univariate logistic regression for parametric values andWilcoxon rank
sum for non‐parametric values. Multivariate logistic regression
models were created using all factors with an alpha <0.10 on
univariate analysis and variables previously identiﬁed as associated
with brain metastases [7] (head and neck primary and ulceration).
Kaplan–Meier survival curves were created to determine differences
in time to recurrence and survival. A P‐value <0.05 were considered
signiﬁcant.
RESULTS
Six hundred seven patients were identiﬁed who were treated for stage
I–III melanoma and subsequently developed distant metastatic disease
during follow‐up after treatment for local or regional melanoma at
MSKCC or UMMC. There were 415 males and 192 females with a
median age of 59 (18–89) years and 53 (20–88) years, respectively.
Three‐hundred three patients presented with stage III disease (50%)
while the remainder had disease limited to the primary site (stage II–
36%, stage I–14%). There were 12 patients (2%) with unknown
primaries, 242 (40%) with lesions located on the trunk, 223 (37%) on an
extremity, and 126 (21%) on the head or neck. Breslow thickness ranged
from 0.3 to 35mm with a mean thickness of 4.3mm. Fifty‐three percent
of the primary lesions were ulcerated and 19% showed evidence of
regression. Angiolymphatic invasion was identiﬁed in 22% of patients
and 13% of patients had primaries with perineural inﬁltration. Primary
melanomas were classiﬁed as either nodular (39%) or superﬁcial
spreading melanomas (35%) with acral (11%), desmoplastic (6%), and
lentigo maligna (3%) comprising the remainder. Mitotic ﬁgures were
identiﬁed in primary tumors from 446 patients with a median number of
four (range 0–50).
Because most patients presented with deep primary lesions or
occasionally palpable adenopathy, regional spread to lymph nodes was
assessed in 93% of patients. Patients without clinically evident regional
disease underwent SLN biopsy (82%). In addition, 102 patients (18%)
had either an elective or therapeutic regional lymphadenectomy. A
median of four lymph nodes were positive in those undergoing any
lymphadenectomy (range 1–54).
At the time of analysis, 450 patients (74%) were dead of disease and
115 (19%) alive with disease. Thirty‐one patients (5%) underwent
metastasectomy or were complete responders to systemic therapy and
had no evidence of residual disease at the most recent follow‐up. Eleven
patients died of “other” or “unknown” causes. The median survival for
all patients was 30 months from diagnosis of the primary and 6 months
from the discovery of metastatic disease.
Of the 607 patients, 120 patients (20%) had brain metastases as part
of their initial distant recurrence. Of the 120 patients, the brain was the
sole site of recurrence in 63 patients (53% of the brainmetastasis cohort).
For those with synchronous recurrence (57 patients), other sites of
disease included the lung (58%), liver (33%), and bone (13%). This did
not differ signiﬁcantly from those with extra‐cranial recurrence, so that
there was nothing “unique” about the pattern of synchronous metastasis
occurring with brain relapse.
To identify factors predictive of CNS failure patients with brain
metastases were compared to those with extra‐cranial recurrence (487
patients). Demographic characteristics for patients with and without
brain metastases are listed in Table I. There was a similar distribution of
gender with 73% and 67% males in the brain metastasis and non‐CNS
metastasis, respectively (P¼ 0.32). Location of the primary lesion did
not differ between groups, with a comparable frequency of head and
neck melanoma (23% and 21%, respectively). Patients with brain
metastases tended to be younger with amedian age of 55 years compared
to 59 years for those with non‐brain metastases (P¼ 0.04). The
distribution of stage at presentation was similar between groups with a
majority of patients with and without brain metastases initially treated
with stage III disease (44% and 49%, respectively).
Histopathologic features of the primary lesion are presented in
Table II. The primary tumors of patients who developed brainmetastases
were signiﬁcantly thinner, with a mean Breslow thickness of 3.43mm,
compared to 4.53mm in patients with no brain metastasis (P¼ 0.01).
There was, however no difference in the Clark level, ulceration,
lymphovascular invasion, regression, or lymphocytic inﬁltrate between
the two groups. On univariate analysis, perineural invasion was
encountered more frequently in the patients with distant extra‐cranial
metastases (15%) compared to those with brain metastasis (7%;
P¼ 0.05). The distribution of histologic subtype was similar between
groups with a slight trend towards more superﬁcial spreading melanoma
in patients with brain relapse.
Antecedent SLN biopsy was more common in patients who
developed brain metastases. There was however, no difference in the
incidence of SLN positivity or total number of positive SLNs. One
hundred four patients who relapsed in the brain had undergone SLN
biopsy, of these 53% were found to be SLN negative (53%). One
hundred eighty of 360 patients who developed stage IV disease without
brain relapse had undergone SLNmapping, of whom 50% (n¼ 180) had
(þ) SLNs (P¼NS). When including patients who underwent
lymphadenectomy without sentinel node biopsy, there were no
differences in total number of positive lymph nodes between the two
groups.
A multivariate logistic regression model was constructed using
variables with P< 0.1 including, Breslow thickness, age, SLN biopsy,
TABLE I. Clinical Features of Patients Treated for Stage I–III Melanoma
WhoDeveloped DistantMetastasis with (n¼ 120) orWithout (n¼ 487) Brain
Recurrence as a Component of Relapse
Brain mets
(n¼ 120)
No brain mets
(n¼ 487) P‐value
Gender 0.32
Male 73% 67%
Female 28% 33%
Age (median) 55 yrs (20–88 yrs) 59 yrs (18–89 yrs) 0.04
Primary Site 0.20
Head and Neck 23% 21%
Extremity 29% 39%
Trunk 47% 38%
Unk primary 2% 2%
Stage at Diagnosis 0.31
I 19% 13%
II 37% 37%
III 44% 49%
Mets, metastasis.
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and perineural invasion (Table III). Also included were variables
previously reported as associated with brain metastases including
ulceration [2,7] and anatomic location of the primary lesion [8]. On
multivariate analysis advanced age was protective of brain metastases
development with an odds ratio of 0.9 per year (P¼ 0.01). Thickness of
the primary lesion was inversely proportional to CNS failure with an
odds ratio of 0.98 per mm of depth.
Kaplan–Meier survival curves were created to determine differences
in overall survival and time to recurrence between patients with and
without brain metastases as a component of initial distant recurrence
(Figs. 1 and 2). While there were no differences in median time to
recurrence (19 months for each group, Fig. 1, P¼ 0.29), the median
survival following diagnosis was signiﬁcantly shorter (6 months) in
those with CNS metastases compared to those with only extra‐cranial
distant metastasis (10 months, P< 0.001, Fig. 2). Both ulceration and
lymph node positivity decreased the time to distant metastasis both in the
brain and elsewhere, but had no effect on post‐metastatic survival (data
not shown).
DISCUSSION
Melanoma represents the third most common metastatic tumor to the
brain, affecting up to 73% of patients with stage IV disease at
autopsy [9]. Adjusting for incidence, melanoma has the greatest
propensity for CNS spread of any primary malignancy [2,10]. The exact
pathophysiology behind this is currently unknown and the source of
active investigation [11–13]. Isolated brain metastases can often be
treated with surgical resection or radiation, with only occasional
cures [14–16]. More commonly, patients present with multiple brain
metastases and are offered corticosteroids and/or radiation for symptom
control. While no data exists regarding the impact of early detection of
brain lesions on survival, prompt treatment with radiotherapy or surgical
resection may decrease the likelihood of neurologic catastrophe due to
edema, hemorrhage, or herniation.
There have beenmultiple prior studies aimed at identifying predictors
of brain metastases in patients with early stage melanoma. Sampson
et al. [2] reported on nearly 7,000 patients treated at a single institution
for primary melanoma over two decades. During follow‐up, 702 (10%)
patients developed clinical or radiographic evidence of brain metastases.
These patients were compared to all other patients in their melanoma
database to identify predictors of brain recurrence. Included in this
comparison cohort were patients with early disease (stage 1 and 2) who
were treated with surgical resection alone and never recurred. Univariate
analysis identiﬁed young age, male gender, trunk location, depth of
invasion, nodular subtype, and ulceration as predictors of development
of brain metastases. Multivariate analysis was not performed. A similar
study by Zakrzewski et al. [7] reported on 900 patients with melanoma
TABLE II. Histologic Features of Primary Lesions from Patients Treated
for Stage I–III Melanoma Who Developed Distant Metastasis with (n¼ 120)
or Without (n¼ 487) Brain Recurrence as a Component of Relapse
With brain mets
(n¼ 120)
No brain mets
(n¼ 487) P‐value
Thickness (mean) 3.43mm 4.53mm 0.01
Clark level 0.20
2 0 2%
3 5% 7%
4 83% 73%
5 12% 18%
Ulceration 0.75
Yes 55% 53%
No 45% 47%
Host response 0.50
None 84% 87%
Slight 1% 2%
Brisk 15% 11%
Regression 0.79
Yes 18% 20%
No 82% 80%
Lymphovasc inv 0.79
Yes 23% 21%
No 77% 79%
Perineural inv 0.05
Yes 6% 15%
No 94% 85%
Satellitosis 0.81
Yes 13% 12%
No 87% 88%
Mitosis (mean) 7.02 7.45 0.61
Histology 0.39
Superficial spr 45% 33%
Nodular 35% 39%
Acral 11% 11%
Desmoplatic 4% 6%
Lentigo malig 1% 4%
Other 5% 6%
Mets, metastasis; inv, invasion; spr, spreading; malig, malignant.
TABLE III. A Multivariate Analysis of Factors Previously Reported as
Associated with Brain Metastases
Odds ratio P‐value
Age (per year) 0.98 0.01
Thickness (per mm) 0.90 0.02
Site 0.27
Trunk (referent) 1
Head and neck 0.97
Extremity 0.64
Ulceration 1.14 0.65
Perineural inv 1.66 0.19
SLN biopsy 1.11 0.73
Young age at initial diagnosis and decreased thickness of the primary lesion were
signiﬁcantly associated with brain relapse when compared to patients who relapse
without brain recurrence.
Inv, invasion; SLN, sentinel lymph node.
Fig. 1. Kaplan–Meier survival curve illustrating time to recurrence
(months) between patients initially treated for stage I–III melanoma who
developed distant metastasis with (top curve) and without brain
metastases (lower curve) as a component of their initial recurrence.
There was no difference in time to presentation with stage IV disease
between the two groups (P¼ 0.29).
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enrolled in a prospective observational database. Demographic data and
pathologic characteristics of the primary lesion in patients who presented
with or developed brain metastases were compared to the remaining
cohort. Again, in this study the comparison cohort included many
patients treated for local disease only who never recurred. This is
highlighted by the fact that 76% of patients in the non‐brain metastases
group had either stage 1 or 2 disease and the overall survival in the cohort
was 90%. On multivariate analysis, the authors identiﬁed ulceration as a
strong predictor of brain metastases with a threefold increased risk of
CNS spread. Another predictor was head and neck location of the
primary which, when compared to trunk or extremity, was 2.5‐fold more
frequent in those with brain relapse. Histologic subtype and Breslow
depth showed no association on multivariate analysis with CNS spread.
While these prior studies represent the largest and most comprehensive
to date, their use of patients with early stage melanoma who never
recurred following local resection as comparators makes interpretation
of results difﬁcult. The predictors identiﬁed may simply represent risk
factors for the development of metastatic disease.
To remedy this, we chose to compare patients who were treated for
stage I–III melanoma and subsequently recurred in the brain to those
who developed distant spread to extracranial sites. Both cohorts include
only stage IV patients thereby eliminating the potential bias towards
overall predictors of metastasis formation. Similar to results found on
univariate analysis by Sampson et al. [2], patients with brain metastases
were younger and had thinner lesions than the extracranial metastatic
cohort. This may suggest a molecular or genetic phenotype which
disseminates hematogenously at an earlier time point. Data supporting
this are the increased expression of matrix metalloproteinases (MMP) in
melanomas associated with greater vascular invasion and possibly early
hematogenous spread [17]. MMPs have also been implicated in brain
metastases in lung [18] and breast cancer [19] suggesting a possible link
between increased MMP expression and brain metastasis. A study be
Xie et al. [20] found that activation of signal transducer and activator of
transcription 3 (Stat3) in melanoma leads to increasedMMP production,
cellular invasion, and brain metastasis in‐vivo.
Other pathologic variables such as regression, lymphocytic inﬁltrate,
and mitoses per high powered ﬁeld were not different between groups
and failed to predict brain relapse. Contrary to prior reports [2,7], there
was no association between ulceration and CNS spread with equal
incidence in both groups. This suggests that the signiﬁcance of
ulceration seen in prior studies may have been due to the use of patients
with early stage melanoma who never recur as the comparison group, as
previously stated. Although on univariate analysis, it appeared that
primary tumors of patients with extra‐cranial metastases had a higher
incidence of perineural invasion, this failed to prove signiﬁcant on
multivariate analysis. The location of the primary tumors was similar
between groups with a trend towards more trunk and fewer extremity
lesions in those with brain metastases. There was no difference in the
presence of head and neck primaries, contrary to prior studies [7].
Patients with brain metastases were more likely to have a sentinel
node biopsy performed although this proved not signiﬁcant on
multivariate analysis. There was no difference in sentinel node
positivity or total number of involved lymph nodes between groups.
This, along with the similarities in lymphovascular invasion of the
primary tumors, suggests no association between regional lymph node
involvement and the development of brain metastases in patients
destined to develop stage IV melanoma.
While identifying high risk patients could allow for improved
screening with neuroimaging, we were unable to ﬁnd useful clinical or
pathologic predictors of brain metastases in early stage patients.
Although these patients tended to be younger and have thinner primary
lesions, these ﬁndings are not useful in identifying a high‐risk
population. Further research is needed to identify novel biomarkers
for neurotropism which may better predict brain metastases in patients
with melanoma. This should alert the clinician to remain vigilant,
however, in patients with a history of melanoma and subtle symptoms of
neurologic concern to consider neuroimaging even in the patient with a
negative SLN biopsy as just over half of the patients with brain relapse in
our study had negative regional lymph nodes.
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